COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties
Abstract Coronavirus disease of 2019 (COVID-19) has emerged as a global health threat. Unfortunately, there are very limited approved drugs available with established efficacy against the SARs-CoV-2 virus and its inflammatory complications. Vaccine development is actively being researched, but it may take over a year to become available to general public. Certain medications, for example, dexamethasone, antimalarials (chloroquine/hydroxychloroquine), antiviral (remdesivir), and IL-6 receptor blocking monoclonal antibodies (tocilizumab), are used in various combinations as off-label medications to treat COVID-19. Essential oils (EOs) have long been known to have anti-inflammatory, immunomodulatory, bronchodilatory, and antiviral properties and are being proposed to have activity against SARC-CoV-2 virus. Owing to their lipophilic nature, EOs are advocated to penetrate viral membranes easily leading to membrane disruption. Moreover, EOs contain multiple active phytochemicals that can act synergistically on multiple stages of viral replication and also induce positive effects on host respiratory system including bronchodilation and mucus lysis. At present, only computer-aided docking and few in vitro studies are available which show anti-SARC-CoV-2 activities of EOs. In this review, role of EOs in the prevention and treatment of COVID-19 is discussed. A discussion on possible side effects associated with EOs as well as anti-corona virus claims made by EOs manufacturers are also highlighted. Based on the current knowledge a chemo-herbal (EOs) combination of the drugs could be a more feasible and effective approach to combat this viral pandemic..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Inflammopharmacology - 28(2020), 5 vom: 14. Aug., Seite 1153-1161 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Asif, Muhammad [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.1007/s10787-020-00744-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR041145445 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR041145445 | ||
| 003 | DE-627 | ||
| 005 | 20230519092043.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10787-020-00744-0 |2 doi | |
| 035 | |a (DE-627)SPR041145445 | ||
| 035 | |a (DE-599)SPRs10787-020-00744-0-e | ||
| 035 | |a (SPR)s10787-020-00744-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Asif, Muhammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Coronavirus disease of 2019 (COVID-19) has emerged as a global health threat. Unfortunately, there are very limited approved drugs available with established efficacy against the SARs-CoV-2 virus and its inflammatory complications. Vaccine development is actively being researched, but it may take over a year to become available to general public. Certain medications, for example, dexamethasone, antimalarials (chloroquine/hydroxychloroquine), antiviral (remdesivir), and IL-6 receptor blocking monoclonal antibodies (tocilizumab), are used in various combinations as off-label medications to treat COVID-19. Essential oils (EOs) have long been known to have anti-inflammatory, immunomodulatory, bronchodilatory, and antiviral properties and are being proposed to have activity against SARC-CoV-2 virus. Owing to their lipophilic nature, EOs are advocated to penetrate viral membranes easily leading to membrane disruption. Moreover, EOs contain multiple active phytochemicals that can act synergistically on multiple stages of viral replication and also induce positive effects on host respiratory system including bronchodilation and mucus lysis. At present, only computer-aided docking and few in vitro studies are available which show anti-SARC-CoV-2 activities of EOs. In this review, role of EOs in the prevention and treatment of COVID-19 is discussed. A discussion on possible side effects associated with EOs as well as anti-corona virus claims made by EOs manufacturers are also highlighted. Based on the current knowledge a chemo-herbal (EOs) combination of the drugs could be a more feasible and effective approach to combat this viral pandemic. | ||
| 650 | 4 | |a Essential oils |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARC-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunomodulatory |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Docking studies |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Saleem, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Saadullah, Malik |e verfasserin |4 aut | |
| 700 | 1 | |a Yaseen, Hafiza Sidra |e verfasserin |4 aut | |
| 700 | 1 | |a Al Zarzour, Raghdaa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d Cham : Springer International Publishing AG, 1991 |g 28(2020), 5 vom: 14. Aug., Seite 1153-1161 |w (DE-627)SPR013448595 |w (DE-600)2047989-X |x 1568-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2020 |g number:5 |g day:14 |g month:08 |g pages:1153-1161 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10787-020-00744-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 28 |j 2020 |e 5 |b 14 |c 08 |h 1153-1161 | ||